Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group

Janna A Hol; Marry M van den Heuvel-Eibrink; Norbert Graf; Kathy Pritchard-Jones; Jesper Brok; Harm van Tinteren; Lisa Howell; Arnauld Verschuur; Christophe Bergeron; Leo Kager; Serena Catania; Filippo Spreafico; Annelies M C Mavinkurve-Groothuis

doi:10.1002/pbc.26849

Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group

Janna A Hol, Marry M van den Heuvel-Eibrink, Norbert Graf, Kathy Pritchard-Jones, Jesper Brok, Harm van Tinteren, Lisa Howell, Arnauld Verschuur, Christophe Bergeron, Leo Kager, Serena Catania, Filippo Spreafico, Annelies M C Mavinkurve-Groothuis

Department of Paediatrics and Adolescent Medicine

8 Citations (Scopus)

Abstract

While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.

Original language	English
Journal	Pediatric Blood and Cancer
Volume	65
Issue number	2
Pages (from-to)	e26849
ISSN	1545-5009
DOIs	https://doi.org/10.1002/pbc.26849
Publication status	Published - Feb 2018

Keywords

Adolescent
Camptothecin
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Kidney Neoplasms
Male
Risk Factors
Wilms Tumor
Clinical Trial
Comparative Study
Journal Article
Multicenter Study

Access to Document

10.1002/pbc.26849

Cite this

Hol, J. A., van den Heuvel-Eibrink, M. M., Graf, N., Pritchard-Jones, K., Brok, J., van Tinteren, H., Howell, L., Verschuur, A., Bergeron, C., Kager, L., Catania, S., Spreafico, F., & Mavinkurve-Groothuis, A. M. C. (2018). Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group. Pediatric Blood and Cancer, 65(2), e26849. https://doi.org/10.1002/pbc.26849

Irinotecan for relapsed Wilms tumor in pediatric patients : SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group. / Hol, Janna A; van den Heuvel-Eibrink, Marry M; Graf, Norbert et al.

In: Pediatric Blood and Cancer, Vol. 65, No. 2, 02.2018, p. e26849.

Research output: Contribution to journal › Journal article › Research › peer-review

Hol, JA, van den Heuvel-Eibrink, MM, Graf, N, Pritchard-Jones, K, Brok, J, van Tinteren, H, Howell, L, Verschuur, A, Bergeron, C, Kager, L, Catania, S, Spreafico, F & Mavinkurve-Groothuis, AMC 2018, 'Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group', Pediatric Blood and Cancer, vol. 65, no. 2, pp. e26849. https://doi.org/10.1002/pbc.26849

@article{ce281f1405e54b7ab19b7f6b4e0272d3,

title = "Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group",

abstract = "While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.",

keywords = "Adolescent, Camptothecin, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Kidney Neoplasms, Male, Risk Factors, Wilms Tumor, Clinical Trial, Comparative Study, Journal Article, Multicenter Study",

author = "Hol, {Janna A} and {van den Heuvel-Eibrink}, {Marry M} and Norbert Graf and Kathy Pritchard-Jones and Jesper Brok and {van Tinteren}, Harm and Lisa Howell and Arnauld Verschuur and Christophe Bergeron and Leo Kager and Serena Catania and Filippo Spreafico and Mavinkurve-Groothuis, {Annelies M C}",

note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2018",

month = feb,

doi = "10.1002/pbc.26849",

language = "English",

volume = "65",

pages = "e26849",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - Irinotecan for relapsed Wilms tumor in pediatric patients

T2 - SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group

AU - Hol, Janna A

AU - van den Heuvel-Eibrink, Marry M

AU - Graf, Norbert

AU - Pritchard-Jones, Kathy

AU - Brok, Jesper

AU - van Tinteren, Harm

AU - Howell, Lisa

AU - Verschuur, Arnauld

AU - Bergeron, Christophe

AU - Kager, Leo

AU - Catania, Serena

AU - Spreafico, Filippo

AU - Mavinkurve-Groothuis, Annelies M C

PY - 2018/2

Y1 - 2018/2

N2 - While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.

AB - While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.

KW - Adolescent

KW - Camptothecin

KW - Child

KW - Child, Preschool

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Kidney Neoplasms

KW - Male

KW - Risk Factors

KW - Wilms Tumor

KW - Clinical Trial

KW - Comparative Study

KW - Journal Article

KW - Multicenter Study

U2 - 10.1002/pbc.26849

DO - 10.1002/pbc.26849

M3 - Journal article

C2 - 29077255

VL - 65

SP - e26849

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -

Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group

Abstract

Keywords

Access to Document

Fingerprint

Cite this